🧾 What This Document Is

This is a 6-K report, which is a form foreign companies like Nanobiotix (based in France) use to tell the U.S. market about important events. This one is essentially a press release sharing the first clinical trial results for one of their key drugs, presented at a major medical conference.

👉 Why it matters: For investors, this is a direct update on the progress of a promising product. Positive data can significantly impact a biotech company's value and future.

🏢 What The Company Does

In simple terms, Nanobiotix is a biotech company trying to revolutionize cancer treatment using physics. They are developing tiny nanoparticles (extremely small particles) that, when injected into a tumor and activated by standard radiotherapy (radiation), are designed to dramatically boost the radiation's cancer-killing effect. Their lead product is JNJ-1900 (also called NBTXR3).

👉 The big idea: They aren't creating a new drug in the traditional sense. Instead, they've built a "radioenhancer" that could potentially make existing radiation therapy much more powerful against solid tumors.

🚀 Key Moves: The CONVERGE Trial Data

The core announcement is the presentation of the first results from the Phase 2 CONVERGE study. This trial is sponsored by their partner, Johnson & Johnson (J&J), and tests JNJ-1900 in patients with Stage 3, inoperable non-small cell lung cancer—a very serious and hard-to-treat condition.

The data, presented at the 2026 European Lung Cancer Conference, showed promising early signals:

Safety: The treatment had an "acceptable safety profile" with no serious treatment-related side effects. Crucially, it did not disrupt the patients' planned follow-up therapy.
Efficacy (Early Signal): In the first 7 patients evaluated, the tumor response was very encouraging:
- Objective Response Rate (ORR): 71.4% of patients saw their tumors shrink significantly. This is well above the estimated benchmark of 45%-50% for this type of treatment.
- Disease Control Rate (DCR): 100% of patients had either tumor shrinkage or stable disease (no growth).

👉 Why it matters: Early-stage data is always viewed with caution, but beating the benchmark by a wide margin in both response and control rates is a strong positive signal that the drug's mechanism works in this new cancer type.

💡 The Drug's Mechanism: How It Works

JNJ-1900 is made of hafnium oxide nanoparticles. Here’s the simple breakdown:

Injection: Doctors inject the nanoparticles directly into the tumor (a one-time procedure).
Activation: When the patient receives standard radiotherapy, the nanoparticles are "activated."
Effect: The activated nanoparticles are designed to release extra energy within the tumor, causing significant cancer cell death. This process is also believed to trigger the body's own immune system to recognize and attack cancer cells, potentially creating a long-term anti-cancer "memory."

👉 The potential: Because this works via a physical mechanism (like a targeted explosion), Nanobiotix believes it could be combined with many different cancer treatments (like immunotherapy) and used against many types of solid tumors.

🤝 The J&J Partnership: A Critical Backdrop

This trial is a major milestone because it's led by Johnson & Johnson, one of the world's largest healthcare companies. In 2023, Nanobiotix signed a license agreement with J&J's Janssen unit for the global co-development and commercialization of JNJ-1900.

👉 Why it matters: Having a giant like J&J invest in and run large trials provides significant validation for Nanobiotix's technology. It also shares the enormous cost and risk of drug development while giving the product a powerful commercial partner if it gets approved.

🔮 What's Next: The Path Forward

This successful Phase 2 data is a building block for the much larger Phase 3 trial called NANORAY-312. This global study is testing JNJ-1900 in locally advanced head and neck cancer, a primary focus area. The new lung cancer data suggests the drug's potential may extend beyond head and neck cancer.

👉 The roadmap: More positive data from ongoing trials (in lung cancer and others) would strengthen the case for JNJ-1900 and could lead to more partnerships or expanded development plans. The ultimate goal is regulatory approval and changing the standard of care.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Novel Mechanism: A unique, physics-based approach that could be a platform technology for multiple cancers.
Powerful Partner: Backed by Johnson & Johnson's resources, expertise, and credibility.
Promising Early Data: The CONVERGE results in lung cancer show a strong signal of efficacy above the standard benchmark.

⚠️ Risks:

Clinical Stage: The company is not yet profitable. Success depends entirely on the continued positive progress and eventual approval of its drug candidates.
Long Road Ahead: Even with good Phase 2 data, Phase 3 trials are large, expensive, and take years to complete with no guarantee of success.
Competition: The oncology field is intensely competitive, with many companies developing new treatments.

🧠 The Analogy

Think of standard radiotherapy like a standard oven. Nanobiotix's JNJ-1900 is like inserting a high-powered convection fan into the tumor. The oven (radiation) stays the same, but the fan (nanoparticle) dramatically amplifies its effect inside, cooking (destroying) the tumor more thoroughly while hopefully leaving the surrounding kitchen (healthy tissue) less affected.

📇 Key Contacts & People

Company Contacts:

Brandon Owens, VP, Communications: +1 (617) 852-4835, [email protected]
Joanne Choi, VP, Investor Relations (US): +1 (713) 609-3150, [email protected]
Ricky Bhajun, Director, Investor Relations (EU): +33 (0) 79 97 29 99, [email protected]
Media Relations (France): Caroline Hardy, +33 06 70 33 49 50, [email protected]
Media Relations (Global): Becky Lauer (uncapped), +1 (646) 286-0057, [email protected]

Trial Investigators (Authors): Includes Benjamin T. Cooper (NYU Langone), Jeffrey D. Bradley (UPenn), Sushma Patel (FirstHealth), and others from study sites and Johnson & Johnson.

🧩 Final Takeaway

Nanobiotix and its deep-pocketed partner, Johnson & Johnson, have released encouraging early data for their "radioenhancer" drug in aggressive lung cancer. While it's just the first step in a long journey, the results validate the core science and suggest the technology may be applicable to more cancer types than previously tested.

Nanobiotix S.A. — 6-K Filing